IAPP Peptides Inhibit Human Amyloid Polypeptide Aggregation
Summary
The USPTO published patent application US20260109744A1 for amyloid peptide variants developed by inventors David Moffet and Luiza Nogaj. The application covers IAPP peptides designed to inhibit aggregation of human Islet Amyloid Polypeptide and their use in preventing amyloid fibril formation. The application was filed on December 17, 2025, under application number 19423936, and received CPC classifications C07K 14/4711, A61P 5/50, and A61K 38/00.
“IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The USPTO published patent application US20260109744A1 covering amyloid peptide variants that inhibit human Islet Amyloid Polypeptide aggregation. The application, filed by inventors David Moffet and Luiza Nogaj on December 17, 2025, describes IAPP peptides designed to prevent amyloid fibril formation with potential therapeutic applications for amyloid-related diseases.
This patent application publication does not create any compliance obligations for pharmaceutical or biotechnology companies. Organizations developing amyloid-targeting therapeutics or diagnostics may wish to monitor this application's prosecution for potential freedom-to-operate considerations, though the mere publication of a patent application does not constitute a granted exclusive right.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AMYLOID PEPTIDE VARIANTS
Application US20260109744A1 Kind: A1 Apr 23, 2026
Inventors
David Moffet, Luiza Nogaj
Abstract
IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.
CPC Classifications
C07K 14/4711 A61P 5/50 A61K 38/00
Filing Date
2025-12-17
Application No.
19423936
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.